Login Register Cart 0
Generic placeholder image

Recent Advances in Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-4344
ISSN (Online): 2772-4352

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Clinical Trial

Atorvastatin Efficacy in the Management of Mild to Moderate Hospitalized COVID-19: A Pilot Randomized Triple-blind Placebo- controlled Clinical Trial

Author(s): Sepideh Hejazi, Farzam Mircheraghi*, Sepideh Elyasi, Najmeh Davoodian*, Davoud Salarbashi and Hassan Mehrad-Majd

Volume 17, Issue 3, 2022

Published on: 19 September, 2022

Page: [212 - 222] Pages: 11

DOI: 10.2174/2772434417666220902153823

Price: $65

Abstract

Background: Statins are first-line lipid-lowering agents with tolerable adverse reactions, low cost, and high availability worldwide. The potent anti-inflammatory, antioxidant, anti-thrombotic and immunomodulatory effects of statins propose them as an option against COVID-19 infection.

Objective: In this randomized triple-blind placebo-controlled clinical trial, we have investigated the atorvastatin efficacy in the management of mild to moderate hospitalized COVID-19 patients.

Methods: In this study, 52 mild to moderate hospitalized COVID-19 patients who fulfilled the inclusion criteria were allocated to the treatment group to receive 40 mg atorvastatin orally once daily for two weeks (n=26) or the placebo group (n=26). Patients' symptoms and laboratory investigations were assessed at baseline and during the follow-up period. We also evaluated the duration of hospitalization and supplemental oxygen therapy as endpoints.

Results: After 14-day of follow-up, the oxygen saturation (SaO2) was significantly higher, and the serum high sensitivity C-reactive protein (hs-CRP) level was lower in the treatment group compared to the placebo group. Moreover, at the end of the followup in the treatment group, the lymphocyte count was higher, and the duration of symptom resolution was shorter but not significant. Additionally, in the treatment group, the length of supplemental oxygen therapy and hospitalization duration were meaningfully shorter. Our results revealed that the mortality rate was almost twice higher in the placebo group compared to the treatment group, without any significant adverse drug reaction.

Conclusion: Atorvastatin significantly reduces supplemental oxygen need, hospitalization duration, and serum hs-CRP level in mild to moderate hospitalized COVID-19 patients.

Keywords: Atorvastatin, COVID-19, anti-inflammatory, clinical response, clinical trial, anti-oxidant.

« Previous Next »
Graphical Abstract

[1]
Davoudi-Monfared E, Rahmani H, Khalili H, et al. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob Agents Chemother 2020; 64(9): e01061-20.
[http://dx.doi.org/10.1128/AAC.01061-20] [PMID: 32661006]
[2]
Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323(16): 1574-81.
[http://dx.doi.org/10.1001/jama.2020.5394] [PMID: 32250385]
[3]
Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020; 180(7): 934-43.
[http://dx.doi.org/10.1001/jamainternmed.2020.0994] [PMID: 32167524]
[4]
Castiglione V. Chiriacò M, Emdin M, Taddei S, Vergaro G. Statin therapy in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother 2020; 6(4): 258-9.
[http://dx.doi.org/10.1093/ehjcvp/pvaa042] [PMID: 32347925]
[5]
Dashti-Khavidaki S, Khalili H. Considerations for statin therapy in patients with COVID‐19. Pharmacotherapy 2020; 40(5): 484-6.
[http://dx.doi.org/10.1002/phar.2397] [PMID: 32267560]
[6]
Fedson DS, Opal SM, Rordam OM. Hiding in plain sight: An approach to treating patients with severe COVID-19 infec-tion. MBio 2020; 11(2): e00398-20.
[http://dx.doi.org/10.1128/mBio.00398-20] [PMID: 32198163]
[7]
Rodrigues-Diez RR. Tejera-Muñoz A, Marquez- Exposito L, et al. Statins: Could an old friend help in the fight against COVID‐19? Br J Pharmacol 2020; 177(21): 4873-86.
[http://dx.doi.org/10.1111/bph.15166] [PMID: 32562276]
[8]
Zhang XJ, Qin JJ, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among indivi-duals with COVID-19. Cell Metab 2020; 32(2): 176-187.e4.
[http://dx.doi.org/10.1016/j.cmet.2020.06.015] [PMID: 32592657]
[9]
Reiner Ž, Hatamipour M, Banach M, et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci 2020; 16(3): 490- 6.
[http://dx.doi.org/10.5114/aoms.2020.94655] [PMID: 32399094]
[10]
Fedson DS. Treating influenza with statins and other immunomodulatory agents. Antiviral Res 2013; 99(3): 417-35.
[http://dx.doi.org/10.1016/j.antiviral.2013.06.018] [PMID: 23831494]
[11]
Papazian L, Roch A, Charles PE, et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial. JAMA 2013; 310(16): 1692-700.
[http://dx.doi.org/10.1001/jama.2013.280031] [PMID: 24108510]
[12]
Pertzov B, Eliakim-Raz N, Atamna H, Trestioreanu AZ, Yahav D, Leibovici L. Hydroxymethylglutaryl-CoA reductase inhibitors (statins) for the treatment of sepsis in adults-a systematic review and meta-analysis. Clin Microbiol Infect 2019; 25(3): 280-9.
[http://dx.doi.org/10.1016/j.cmi.2018.11.003] [PMID: 30472427]
[13]
Sapey E, Patel JM, Greenwood H, et al. Simvastatin improves neutrophil function and clinical outcomes in pneumonia. A pilot randomized controlled clinical trial. Am J Respir Crit Care Med 2019; 200(10): 1282-93.
[http://dx.doi.org/10.1164/rccm.201812-2328OC] [PMID: 31206313]
[14]
Shrivastava-Ranjan P, Flint M. Bergeron É, et al. Statins suppress ebola virus infectivity by interfering with glycoprotein processing. MBio 2018; 9(3): e00660-18.
[http://dx.doi.org/10.1128/mBio.00660-18] [PMID: 29717011]
[15]
Bifulco M, Gazzerro P. Statin therapy in COVID-19 infection: much more than a single pathway. Eur Heart J Cardiovasc Pharmacother 2020; 6(6): 410-1.
[http://dx.doi.org/10.1093/ehjcvp/pvaa055] [PMID: 32529218]
[16]
Arabi YM, Fowler R, Hayden FG. Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med 2020; 46(2): 315-28.
[http://dx.doi.org/10.1007/s00134-020-05943-5] [PMID: 32040667]
[17]
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blo-cked by a clinically proven protease inhibitor. Cell 2020; 181(2): 271-280.e8.
[http://dx.doi.org/10.1016/j.cell.2020.02.052] [PMID: 32142651]
[18]
Shin YH, Min JJ, Lee JH, et al. The effect of fluvastatin on cardiac fibrosis and angiotensin-converting enzyme-2 ex-pression in glucose-controlled diabetic rat hearts. Heart Vessels 2017; 32(5): 618-27.
[http://dx.doi.org/10.1007/s00380-016-0936-5] [PMID: 28013371]
[19]
Wang Q, Zhang Y, Wu L, et al. Structural and functional basis of SARS-CoV-2 entry by using human ACE2. Cell 2020; 181(4): 894-904.e9.
[http://dx.doi.org/10.1016/j.cell.2020.03.045] [PMID: 32275855]
[20]
Subir R, Jagat JM, Kalyan KG. Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19). Diabetes Metab Syndr 2020; 14(5): 1225-9.
[http://dx.doi.org/10.1016/j.dsx.2020.07.011] [PMID: 32683320]
[21]
Ho PM, Bryson CL, Rumsfeld JS. Medication adherence. Circulation 2009; 119(23): 3028-35.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.108.768986] [PMID: 19528344]
[22]
Whitehead AL, Julious SA, Cooper CL, Campbell MJ. Estimating the sample size for a pilot randomised trial to minimi-se the overall trial sample size for the external pilot and main trial for a continuous outcome variable. Stat Methods Med Res 2016; 25(3): 1057-73.
[http://dx.doi.org/10.1177/0962280215588241] [PMID: 26092476]
[23]
Blum A, Shamburek R. The pleiotropic effects of statins on endothelial function, vascular inflammation, immunomo-dulation and thrombogenesis. Atherosclerosis 2009; 203(2): 325-30.
[http://dx.doi.org/10.1016/j.atherosclerosis.2008.08.022] [PMID: 18834985]
[24]
Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45(1): 89-118.
[http://dx.doi.org/10.1146/annurev.pharmtox.45.120403.095748] [PMID: 15822172]
[25]
Parihar SP, Guler R, Brombacher F. Statins: A viable candidate for host-directed therapy against infectious diseases. Nat Rev Immunol 2019; 19(2): 104-17.
[http://dx.doi.org/10.1038/s41577-018-0094-3] [PMID: 30487528]
[26]
Endres M. Statins: Potential new indications in inflammatory conditions. Atheroscler Suppl 2006; 7(1): 31-5.
[http://dx.doi.org/10.1016/j.atherosclerosissup.2006.01.005] [PMID: 16503422]
[27]
Mehrbod P, Omar AR, Hair-Bejo M, Haghani A, Ideris A. Mechanisms of action and efficacy of statins against in-fluenza. BioMed Res Int 2014; 2014: 1-8.
[http://dx.doi.org/10.1155/2014/872370] [PMID: 25478576]
[28]
Vandermeer ML, Thomas AR, Kamimoto L, et al. Association between use of statins and mortality among patients hospitalized with laboratory-confirmed influenza virus infections: A multistate study. J Infect Dis 2012; 205(1): 13-9.
[http://dx.doi.org/10.1093/infdis/jir695] [PMID: 22170954]
[29]
Andrews L, Goldin L, Shen Y, et al. Discontinuation of atorvastatin use in hospital is associated with increased risk of mortality in COVID‐19 patients. J Hosp Med 2022; 17(3): 169-75.
[http://dx.doi.org/10.1002/jhm.12789] [PMID: 35504528]
[30]
Gupta A, Madhavan MV, Poterucha TJ, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nat Commun 2021; 12(1): 1325.
[http://dx.doi.org/10.1038/s41467-021-21553-1] [PMID: 33637713]
[31]
Peymani P, Dehesh T, Aligolighasemabadi F, et al. Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients. Transl Med Commun 2021; 6(1): 3.
[http://dx.doi.org/10.1186/s41231-021-00082-5] [PMID: 33521322]
[32]
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352(16): 1685-95.
[http://dx.doi.org/10.1056/NEJMra043430] [PMID: 15843671]
[33]
Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359(21): 2195-207.
[http://dx.doi.org/10.1056/NEJMoa0807646] [PMID: 18997196]
[34]
Song SL, Hays SB, Panton CE, et al. Statin use is associated with decreased risk of invasive mechanical ventilation in COVID-19 Patients: A preliminary study. Pathogens 2020; 9(9): 759.
[http://dx.doi.org/10.3390/pathogens9090759] [PMID: 32957539]
[35]
Hariyanto TI, Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (CO-VID-19) infection. Diabetes Metab Syndr 2020; 14(6): 1613-5.
[http://dx.doi.org/10.1016/j.dsx.2020.08.023] [PMID: 32882643]
[36]
Sadeghipour P. Atorvastatin versus placebo in patients with covid-19 in intensive care: Randomized controlled trial. BMJ 2022; 376: e068407.
[PMID: 34996756]
[37]
Holtzman CW, Wiggins BS, Spinler SA. Role of P-glycoprotein in statin drug interactions. Pharmacotherapy 2006; 26(11): 1601-7.
[http://dx.doi.org/10.1592/phco.26.11.1601] [PMID: 17064205]
[38]
Tseng A, Hughes CA, Wu J, Seet J, Phillips EJ. Cobicistat versus ritonavir: Similar pharmacokinetic enhancers but some important differences. Ann Pharmacother 2017; 51(11): 1008-22.
[http://dx.doi.org/10.1177/1060028017717018] [PMID: 28627229]
[39]
Agarwal S, Agarwal SK. Lopinavir-ritonavir in SARS-CoV-2 infection and drug-drug interactions with cardioactive me-dications. Cardiovasc Drugs Ther 2021; 35(3): 427-40.
[http://dx.doi.org/10.1007/s10557-020-07070-1] [PMID: 32918656]
[40]
Marzolini C, Gibbons S, Khoo S, Back D. Cobicistat versus ritonavir boosting and differences in the drug–drug interacti-on profiles with co-medications. J Antimicrob Chemother 2016; 71(7): 1755-8.
[http://dx.doi.org/10.1093/jac/dkw032] [PMID: 26945713]
[41]
Lepist EI, Phan TK, Roy A, et al. Cobicistat boosts the intestinal absorption of transport substrates, including HIV pro-tease inhibitors and GS-7340, in vitro. Antimicrob Agents Chemother 2012; 56(10): 5409-13.
[http://dx.doi.org/10.1128/AAC.01089-12] [PMID: 22850510]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy